Public biopharmaceutical company fundraising activity in late June and early July was somewhat remarkable after the BIO International Convention in early June, during which drug developers and investo
The market for biopharmaceutical company initial public offerings and follow-on public offerings has become more friendly this year, but some firms still are circumventing the public offering route an
Ionis Pharmaceuticals Inc. has been in it for the long haul, developing antisense drugs for more than 25 years. But now partnered and independently-owned drugs are in late-stage development and the
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions leading up to the J.P. Morgan Healthcare C